A/Prof. Olivia Dean

STAFF PROFILE

Position

Associate Professor (Research)

Faculty

Faculty of Health

Department

School of Medicine

Campus

HERB

Contact

o.dean@deakin.edu.au
+61342153300

Publications

Filter by

2019

Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice Jacka, Susan Cotton, Jon-Paul Khoo, Mary Chatterton, Bianca Kavanagh, Sarah Nadjidai, Samantha Lo Monaco, Brian Harvey, Jerome Sarris, Gin Malhi, Nathan Dowling, Olivia Dean

(2019), Vol. 41, pp. 245-253, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

journal

The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study

Pernille Ellegaard, Rasmus Licht, Ren Nielsen, Olivia Dean, Michael Berk, Henrik Poulsen, Mohammadreza Mohebbi, Connie Nielsen

(2019), Vol. 245, pp. 1043-1051, Journal of affective disorders, Amsterdam, The Netherlands, C1

journal

A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo

Michael Berk, Alyna Turner, Gin Malhi, Chee Ng, Susan Cotton, Seetal Dodd, Yuval Samuni, Michelle Tanious, Claire McAulay, Nathan Dowling, Jerome Sarris, Lauren Owen, Astrid Waterdrinker, Deidre Smith, Olivia Dean

(2019), Vol. 17, pp. 1-11, BMC medicine, London, Eng., C1

journal

The therapeutic potential of mangosteen pericarp as an adjunctive therapy for bipolar disorder and schizophrenia

Melanie Ashton, Olivia Dean, Adam Walker, Chiara Bortolasci, Chee Ng, Malcolm Hopwood, Brian Harvey, Marisa Mller, John McGrath, Wolfgang Marx, Alyna Turner, Seetal Dodd, James Scott, Jon-Paul Khoo, Ken Walder, Jerome Sarris, Michael Berk

(2019), Vol. 10, pp. 1-17, Frontiers in psychiatry, Lausanne, Switzerland, C1

journal

Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Alyna Turner, John McGrath, Olivia Dean, Seetal Dodd, Andrea Baker, Susan Cotton, James Scott, Bianca Kavanagh, Melanie Ashton, Adam Walker, Ellie Brown, Michael Berk

(2019), Vol. 17, pp. 297-307, Clinical psychopharmacology and neuroscience, Seoul, South Korea, C1

journal

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Bianca Kavanagh, Lana Williams, Jerome Sarris, Olivia Dean

(2019), Vol. 9, BMJ Open, London, Eng., C1

journal

Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis

Carmen Lim, Andrea Baker, Sukanta Saha, Sharon Foley, Anne Gordon, David Ward, Bjorn Burgher, Frances Dark, Martin Beckmann, Stephen Stathis, George Bruxner, Alex Ryan, Drew Richardson, Sean Hatherill, Michael Berk, Olivia Dean, John McGrath, Cadence Working Group, James Scott

(2019), Vol. 20, Trials, London, Eng., C1

journal

The effect of blueberry interventions on cognitive performance and mood: a systematic review of randomized controlled trials

Nikolaj Travica, Nathan D'Cunha, Nenad Naumovski, Katherine Kent, Duane Mellor, Joseph Firth, Ekavi Georgousopoulou, Olivia Dean, Amy Loughman, Felice Jacka, Wolfgang Marx

(2019), Brain, behavior and immunity, Amsterdam, The Netherlands, C1

journal

Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis

Bianca Kavanagh, Sharon Brennan-Olsen, Alyna Turner, Olivia Dean, Michael Berk, Melanie Ashton, Heli Koivumaa-Honkanen, Lana Williams

(2019), Vol. 9, BMJ open, London, Eng., C1

journal

Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial

Bianca Kavanagh, Lana Williams, Michael Berk, Alyna Turner, Henry Jackson, Mohammadreza Mohebbi, Buranee Kanchanatawan, Melanie Ashton, Chee Ng, Michael Maes, Lesley Berk, Gin Malhi, Nathan Dowling, Ajeet Singh, Olivia Dean

(2019), Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

journal

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis

Wolfgang Marx, Melissa Lane, Tetyana Rocks, Anu Ruusunen, Amy Loughman, Adrian Lopresti, Skye Marshall, Michael Berk, Felice Jacka, Olivia Dean

(2019), Vol. 77, pp. 557-571, Nutrition reviews, Oxford, Eng., C1

journal

A study protocol for the N-ICE trial: a randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence

Rebecca McKetin, Olivia Dean, Alyna Turner, Peter Kelly, Brendan Quinn, Dan Lubman, Paul Dietze, Gregory Carter, Peter Higgs, Amanda Baker, Barbara Sinclair, David Reid, Victoria Manning, Nina Te Pas, Wenbin Liang, Tamsin Thomas, Ramez Bathish, Margaret Kent, Dayle Raftery, Shalini Arunogiri, Frank Cordaro, Harry Hill, Michael Berk

(2019), Vol. 20, pp. 1-11, Trials, London, Eng., C1

journal

Measuring cognitive insight in people with problematic substance use: an exploration of the factor validity of the Beck Cognitive Insight Scale

D Raftery, P Kelly, F Deane, R Mcketin, A Baker, A Turner, O Dean

(2019), Vol. 38, pp. 622-629, Drug and alcohol review, Chichester, Eng., C1

journal

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial

C Davey, A Chanen, S Hetrick, S Cotton, A Ratheesh, G Amminger, J Koutsogiannis, M Phelan, E Mullen, B Harrison, S Rice, A Parker, O Dean, A Weller, M Kerr, A Quinn, L Catania, N Kazantzis, P McGorry, M Berk

(2019), Vol. 6, pp. 735-744, The Lancet Psychiatry, Amsterdam, The Netherlands, C1

journal

Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline

K Hasebe, L Rivera, C Smith, T Allnutt, T Crowley, T Nelson, O Dean, S McGee, K Walder, L Gray

(2019), Vol. 82, pp. 309-318, Brain, behavior, and immunity, Amsterdam, The Netherlands, C1

journal

N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial

L Arancini, C Bortolasci, S Dodd, O Dean, M Berk

(2019), Vol. 20, pp. 1-7, Trials, London, Eng., C1

journal

Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis - A possible therapeutic mechanism

S Kidnapillai, C Bortolasci, B Panizzutti, B Spolding, T Connor, K Bonifacio, A Sanigorski, O Dean, T Crowley, S Jamain, L Gray, M Leboyer, M Berk, K Walder

(2019), pp. 1-12, World Journal of Biological Psychiatry, London, Eng., C1

journal
2018

Youth depression alleviation-augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin

A Quinn, O Dean, C Davey, M Kerr, S Harrigan, S Cotton, A Chanen, S Dodd, A Ratheesh, G Amminger, M Phelan, A Williams, A Mackinnon, F Giorlando, S Baird, S Rice, M O'Shea, M Schfer, E Mullen, S Hetrick, P McGorry, M Berk

(2018), Vol. 12, pp. 45-54, Early intervention in psychiatry, London, Eng., C1

journal

Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat

I Oberholzer, M Mller, B Holland, O Dean, M Berk, B Harvey

(2018), Vol. 33, pp. 467-480, Metabolic brain disease, New York, N.Y., C1

journal

Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapies

D Skvarc, M Berk, L Byrne, O Dean, S Dodd, M Lewis, A Marriott, E Moore, G Morris, R Page, L Gray

(2018), Vol. 84, pp. 116-133, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

An update on adjunctive treatment options for bipolar disorder

O Dean, E Gliddon, T Van Rheenen, F Giorlando, S Davidson, M Kaur, T Ngo, L Williams

(2018), Vol. 20, pp. 87-96, Bipolar disorders, Chichester, Eng., C1

journal

Mechanisms underpinning the polypharmacy effects of medications in psychiatry

Chiara Bortolasci, Briana Spolding, Edward Callaly, Sheree Martin, Bruna Panizzutti, Srisaiyini Kidnapillai, Timothy Connor, Kyoko Hasebe, Mohammadreza Mohebbi, Olivia Dean, Sean McGee, Seetal Dodd, Laura Gray, Michael Berk, Ken Walder

(2018), Vol. 21, pp. 582-591, The international journal of neuropsychopharmacology, Oxford, Eng., C1

journal

Mitochondrial agents for bipolar disorder

Cria Pereira, Victor Chavarria, Joo Vian, Melanie Ashton, Michael Berk, Wolfgang Marx, Olivia Dean

(2018), Vol. 21, pp. 550-569, International journal of neuropsychopharmacology, London, Eng., C1

journal

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)

P Ellegaard, R Licht, H Poulsen, R Nielsen, M Berk, O Dean, M Mohebbi, C Nielsen

(2018), Vol. 6, pp. 1-9, International journal of bipolar disorders, Berlin, Germany, C1

journal

Does N-acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of N-acetylcysteine

O Dean, K Gray, Seetal Dodd, K Villagonzalo, E Browne, B Tonge, M Berk, L Byrne

(2018), pp. 1-7, Journal of intellectual and developmental disability, London, Eng., C1

journal

Improvement of cognitive function in schizophrenia with N-acetylcysteine: a theoretical review

C Yolland, A Phillipou, D Castle, E Neill, M Hughes, C Galletly, Z Smith, P Francis, O Dean, J Sarris, D Siskind, A Harris, S Rossell

(2018), pp. 1-10, Nutritional neuroscience, Abingdon, Eng., C1

journal

Patient centric measures for a patient centric era: agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder

M Mohebbi, S Dodd, O Dean, M Berk

(2018), Vol. 53, pp. 17-22, European psychiatry, Amsterdam, The Netherlands, C1

journal

The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder

Srisaiyini Kidnapillai, Chiara Bortolasci, Madhara Udawela, Bruna Panizzutti, Briana Spolding, Timothy Connor, Andrew Sanigorski, Olivia Dean, Tamsyn Crowley, Stphane Jamain, Laura Gray, Elizabeth Scarr, Marion Leboyer, Brian Dean, Michael Berk, Ken Walder

(2018), pp. 1-9, World journal of biological psychiatry, London, Eng., C1

journal

Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression

Bruna Panizzutti, Chiara Bortolasci, Kyoko Hasebe, Srisaiyini Kidnapillai, Laura Gray, Ken Walder, Michael Berk, Mohammadreza Mohebbi, Seetal Dodd, Clarissa Gama, Pedro Magalhes, Susan Cotton, Flvio Kapczinski, Ashley Bush, Gin Malhi, Olivia Dean

(2018), Vol. 30, pp. 334-341, Acta neuropsychiatrica, Cambridge, Eng., C1

journal
2017

A potential role for N-acetylcysteine in the management of methamphetamine dependence

R McKetin, O Dean, A Baker, G Carter, A Turner, P Kelly, M Berk

(2017), Vol. 36, pp. 153-159, Drug and alcohol review, London, Eng., C1

journal

A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder

O Dean, K Gray, K-A Villagonzalo, S Dodd, M Mohebbi, T Vick, B Tonge, M Berk

(2017), Vol. 51, pp. 241-249, Australian and New Zealand journal of psychiatry, London, Eng., C1

journal

Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology

J Data-Franco, A Singh, D Popovic, M Ashton, M Berk, E Vieta, M Figueira, O Dean

(2017), Vol. 72, pp. 73-86, Progress in neuro-psychopharmacology & biological psychiatry, Amsterdam, The Netherlands, C1

journal

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

M Rapado-Castro, S Dodd, A Bush, G Malhi, D Skvarc, Z On, M Berk, O Dean

(2017), Vol. 47, pp. 866-876, Psychological medicine, Cambridge, Eng., C1

journal

A model of the mitochondrial basis of bipolar disorder

G Morris, K Walder, S McGee, O Dean, S Tye, M Maes, M Berk

(2017), Vol. 74, pp. 1-20, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial)

F Jacka, A O'Neil, R Opie, C Itsiopoulos, S Cotton, M Mohebbi, D Castle, S Dash, C Mihalopoulos, M Chatterton, L Brazionis, O Dean, A Hodge, M Berk

(2017), Vol. 15, pp. 1-13, BMC medicine, London, Eng., C1

journal

A review of the theoretical and biological understanding of the nocebo and placebo phenomena

S Dodd, O Dean, J Vian, M Berk

(2017), Vol. 39, pp. 469-476, Clinical therapeutics, Amsterdam, The Netherlands, C1

journal

Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor

K Hasebe, L Gray, C Bortolasci, B Panizzutti, M Mohebbi, S Kidnapillai, B Spolding, K Walder, M Berk, G Malhi, S Dodd, O Dean

(2017), Vol. 29, pp. 337-346, Acta neuropsychiatrica, Cambridge, Eng., C1

journal

The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - Cadence-BZ: study protocol for a randomized controlled trial

A Ryan, A Baker, F Dark, S Foley, A Gordon, S Hatherill, S Stathis, S Saha, G Bruxner, M Beckman, D Richardson, M Berk, O Dean, J McGrath, Cadence Working Group, J Scott

(2017), Vol. 18, pp. 1-11, Trials, London, Eng., C1

journal

the effect of n-acetylcysteine (nac) on human cognition - a systematic review

D Skvarc, O Dean, L Byrne, L Gray, S Lane, M Lewis, B Fernandes, M Berk, A Marriott

(2017), Vol. 78, pp. 44-56, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal

Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial

O Dean, B Kanchanatawan, M Ashton, M Mohebbi, C Ng, M Maes, L Berk, A Sughondhabirom, S Tangwongchai, A Singh, H McKenzie, D Smith, G Malhi, N Dowling, M Berk

(2017), Vol. 51, pp. 829-840, Australian & New Zealand journal of psychiatry, London, Eng., C1

journal

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: a 16-week open-label pilot study

R Menon, L Cribb, J Murphy, M Ashton, G Oliver, N Dowling, A Turner, O Dean, M Berk, C Ng, J Sarris

(2017), Vol. 4, pp. 109-114, Advances in integrative medicine, Amsterdam, The Netherlands, C1

journal
2016

C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications

B Fernandes, J Steiner, H Bernstein, S Dodd, J Pasco, O Dean, P Nardin, C Gonalves, M Berk

(2016), Vol. 21, pp. 554-564, Molecular psychiatry, London, Eng., C1

journal

A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis

J Davis, H Eyre, F Jacka, S Dodd, O Dean, S McEwen, M Debnath, J McGrath, M Maes, P Amminger, P McGorry, C Pantelis, M Berk

(2016), Vol. 65, pp. 185-194, Neuroscience & biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

Antioxidant treatments for schizophrenia

P Magalhes, O Dean, A Andreazza, M Berk, F Kapczinski

(2016), Vol. 2016, pp. 1-93, Cochrane database of systematic reviews, London, Eng., C1

journal

N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis

B Fernandes, O Dean, S Dodd, G Malhi, M Berk

(2016), Vol. 77, pp. 457-466, Journal of clinical psychiatry, Memphis, Tenn., C1

journal

The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial

D Skvarc, O Dean, L Byrne, L Gray, K Ives, S Lane, M Lewis, C Osborne, R Page, D Stupart, A Turner, M Berk, A Marriott

(2016), Vol. 17, pp. 1-11, Trials, London, Eng., C1

journal

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms

S Rossell, P Francis, C Galletly, A Harris, D Siskind, M Berk, K Bozaoglu, F Dark, O Dean, D Liu, D Meyer, E Neill, A Phillipou, J Sarris, D Castle

(2016), Vol. 16, pp. 1-9, BMC psychiatry, London, Eng., C1

journal

Participant characteristics as modifiers of response to N-Acetyl cysteine (NAC) in obsessive-compulsive disorder

J Sarris, G Oliver, D Camfield, O Dean

(2016), Vol. 4, pp. 1104-1111, Clinical psychological science, London, Eng., C1

journal
2015

Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

M Rapado-Castro, M Berk, K Venugopal, A Bush, S Dodd, O Dean

(2015), Vol. 57, pp. 69-75, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Amsterdam, The Netherlands, C1

journal

Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols?

S Nabavi, O Dean, A Turner, A Sureda, M Daglia, S Nabavi

(2015), Vol. 22, pp. 343-351, Current medicinal chemistry, Beijing, China, C1-1

journal

Tobacco use in bipolar disorder.

D Thomson, M Berk, S Dodd, M Rapado-Castro, S Quirk, P Ellegaard, L Berk, O Dean

(2015), Vol. 13, pp. 1-11, Clinical Psychopharmacology and Neuroscience, Korea (South), C1

journal

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review

G Oliver, O Dean, D Camfield, S Blair-West, C Ng, M Berk, J Sarris

(2015), Vol. 13, pp. 12-24, Clinical psychopharmacology and neuroscience, Korea (South), C1

journal

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Deepmala, J Slattery, N Kumar, L Delhey, M Berk, O Dean, C Spielholz, R Frye

(2015), Vol. 55, pp. 294-321, Neuroscience and Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal

N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study

J Sarris, G Oliver, D Camfield, O Dean, N Dowling, D Smith, J Murphy, R Menon, M Berk, S Blair-West, C Ng

(2015), Vol. 29, pp. 801-809, CNS Drugs, Berlin, Germany, C1

journal

Future directions for pharmacotherapies for treatment-resistant bipolar disorder

S Dodd, B Simoes Fernandes, O Dean

(2015), Vol. 13, pp. 656-662, Current neuropharmacology, Bussum, The Netherlands, C1

journal

The use of mixed methods in drug discovery: integrating qualitative methods into clinical trials

M Berk, R Otmar, O Dean, L Berk, E Michalak

(2015), pp. 59-73, Clinical trial design challenges in mood disorders, Amsterdam, The Netherlands, B1

chapter
2014

Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: Therapeutic implications

G Anderson, M Berk, O Dean, S Moylan, M Maes

(2014), Vol. 28, pp. 1-10, CNS Drugs, C1

journal

Post-stroke depression therapy: Where are we now?

S Nabavi, A Turner, O Dean, A Sureda, S Nabavi

(2014), Vol. 11, pp. 279-289, Current Neurovascular Research, C1

journal

The efficacy of adjunctive N-Acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

M Berk, O Dean, S Cotton, S Jeavons, M Tanious, K Kohlmann, K Hewitt, K Moss, C Allwang, I Schapkaitz, J Robbins, H Cobb, F Ng, S Dodd, A Bush, G Malhi

(2014), Vol. 75, pp. 628-636, Journal of clinical psychiatry, Memphis, Tenn., C1

journal

Oxidative & nitrosative stress in depression: why so much stress?

S Moylan, M Berk, O Dean, Y Samuni, L Williams, A O'Neil, A Hayley, J Pasco, G Anderson, F Jacka, M Maes

(2014), Vol. 45, pp. 46-62, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

O Dean, A Turner, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, Y Samuni, M Tanious, N Dowling, A Waterdrinker, D Smith, M Berk

(2014), Vol. 0, pp. 1-10, Revista Brasileira de psiquiatria, Sao Paulo, Brazil, C1

journal

The Glutathione System: a new drug target in neuroimmune disorders

G Morris, G Morris, G Anderson, G Anderson, O Dean, O Dean, M Berk, M Berk, P Galecki, P Galecki, M Martin-Subero, M Martin-Subero, M Maes, M Maes

(2014), Vol. 50, pp. 1059-1084, Molecular neurobiology, New York, N. Y., C1

journal

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.

C Davey, A Chanen, S Cotton, S Hetrick, M Kerr, M Berk, O Dean, K Yuen, M Phelan, A Ratheesh, M Schfer, G Amminger, A Parker, D Piskulic, S Harrigan, A Mackinnon, B Harrison, P McGorry

(2014), Vol. 15, pp. 1-9, Trials, London, Eng., C1

journal

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial.

O Dean, M Maes, M Ashton, L Berk, B Kanchanatawan, A Sughondhabirom, S Tangwongchai, C Ng, N Dowling, G Malhi, M Berk

(2014), Vol. 12, pp. 180-188, Clinical psychopharmacology and neuroscience, Seoul, Korea, C1

journal
2013

Putative neuroprotective agents in neuropsychiatric disorders

S Dodd, M Maes, G Anderson, O Dean, S Moylan, M Berk

(2013), Vol. 42, pp. 135-145, Progress in Neuro-Psychopharmacology and Biological Psychiatry, C1

journal

The promise of N-acetylcysteine in neuropsychiatry

M Berk, G Malhi, L Gray, O Dean

(2013), Vol. 34, pp. 167-177, Trends in Pharmacological Sciences, C1

journal

Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo

P Das, M Tanious, K Fritz, S Dodd, O Dean, M Berk, G Malhi

(2013), Vol. 47, pp. 347-354, Australian and New Zealand Journal of Psychiatry, C1

journal

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania

P Da Silva Magalhes, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2013), Vol. 47, pp. 564-568, Australian and New Zealand Journal of Psychiatry, C1

journal

Aspirin: A review of its neurobiological properties and therapeutic potential for mental illness

M Berk, M Berk, O Dean, O Dean, H Drexhage, H Drexhage, J McNeil, J McNeil, S Moylan, S Moylan, A O'Neil, A O'Neil, C Davey, C Davey, L Sanna, L Sanna, M Maes, M Maes

(2013), Vol. 11, pp. 1-17, BMC Medicine, C1

journal

A randomised, controlled trial of a dietary intervention for adults with major depression (the "SMILES" trial): Study protocol

A O'Neil, M Berk, C Itsiopoulos, D Castle, R Opie, J Pizzinga, L Brazionis, A Hodge, C Mihalopoulos, M Chatterton, O Dean, F Jacka

(2013), Vol. 13, BMC Psychiatry, C1

journal

The chemistry and biological activities of N-acetylcysteine

Y Samuni, S Goldstein, O Dean, M Berk

(2013), Vol. 1830, pp. 4117-4129, Biochimica et Biophysica Acta - General Subjects, C1

journal
2012

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

P Magalhes, O Dean, A Bush, D Copolov, D Weisinger, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 37, pp. 132-135, Progress in Neuro-Psychopharmacology and Biological Psychiatry, C1

journal

Minocycline: Therapeutic potential in psychiatry

O Dean, J Data-Franco, F Giorlando, M Berk

(2012), Vol. 26, pp. 391-401, CNS Drugs, C1

journal

Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, K Moss, C Allwang, I Schapkaitz, H Cobb, A Bush, S Dodd, G Malhi

(2012), Vol. 10, BMC Medicine, C1

journal

Adjunctive antioxidants for bipolar disorder

P Magalhaes, O Dean, A Andreazza, M Berk, F Kapczinski

(2012), pp. 1-11, The Cochrane collaboration, Oxford, England, C1-1

journal

Effects of N-acetyl cysteine on cognitive function in bipolar disorder

O Dean, A Bush, D Copolov, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 66, pp. 514-517, Psychiatry and Clinical Neurosciences, C1

journal

Glutamatergic antidepressants

H Kalra, O Dean, S Dodd, M Berk

(2012), pp. 95-107, Antidepressants and Major Depressive Disorder, B1-1

chapter
2011

Qualitative methods in early-phase drug trials : data and methods from a trial of N-acetylcysteine in schizophrenia

M Berk, A Munib, O Dean, G Malhi, K Kohlmann, I Schapkaitz, S Jeavons, F Katz, M Anderson-Hunt, P Conus, B Hanna, R Otmar, F Ng, D Copolov, A Bush

(2011), Vol. 72, pp. 909-913, Journal of clinical psychiatry, [Memphis, Tenn.], C1-1

journal

N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action

O Dean, F Giorlando, M Berk

(2011), Vol. 36, pp. 78-86, Journal of Psychiatry and Neuroscience, C1-1

journal

N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder

O Dean, M Van Den Buuse, M Berk, D Copolov, C Mavros, A Bush

(2011), Vol. 499, pp. 149-153, Neuroscience Letters, C1-1

journal

Role of dopamine D 3 and serotonin 5-HT 1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine- lesioned rat model of Parkinson's disease

M Gerlach, G Bartoszyk, P Riederer, O Dean, M Van Den Buuse

(2011), Vol. 118, pp. 1733-1742, Journal of Neural Transmission, C1-1

journal

Antioxidant treatments for schizophrenia

P Magalhaes, A Andreazza, M Berk, F Kapczinski, O Dean

(2011), pp. 1-13, Cochrane database of systematic reviews, Oxford, U. K., C1-1

journal

N-acetyl cysteine add-on treatment for bipolar II disorder: A subgroup analysis of a randomized placebo-controlled trial

P Magalhes, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 129, pp. 317-320, Journal of Affective Disorders, C1-1

journal

Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder

P Magalhes, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 23, pp. 87-88, Acta Neuropsychiatrica, C1-1

journal

Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors

M Berk, F Kapczinski, A Andreazza, O Dean, F Giorlando, M Maes, M Ycel, C Gama, S Dodd, B Dean, P Magalhes, P Amminger, P McGorry, G Malhi

(2011), Vol. 35, pp. 804-817, Neuroscience and Biobehavioral Reviews, C1-1

journal

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, C Allwang, H Cobb, A Bush, I Schapkaitz, S Dodd, G Malhi

(2011), Vol. 135, pp. 389-394, Journal of Affective Disorders, C1

journal

Who's left? Symptoms of schizophrenia that predict clinical trial dropout

J Thompson, M Berk, O Dean, K Kohlmann, S Jeavons, A Bush, D Copolov

(2011), Vol. 26, pp. 609-613, Human Psychopharmacology, C1-1

journal

N-acetylcysteine for major depressive episodes in bipolar disorder

P Magalhes, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 33, pp. 374-378, Revista Brasileira de Psiquiatria, C1

journal
2010

Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats

K Choy, O Dean, M Berk, A Bush, M van den Buuse

(2010), Vol. 649, pp. 224-228, European Journal of Pharmacology, C1-1

journal

Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2010), Vol. 97, pp. 293-300, Pharmacology Biochemistry and Behavior, C1-1

journal

Oxidative pathways as a drug target for the treatment of autism

K Villagonzalo, S Dodd, O Dean, K Gray, B Tonge, M Berk

(2010), Vol. 14, pp. 1301-1310, Expert Opinion on Therapeutic Targets, C1-1

journal

The validity and internal structure of the Bipolar Depression Rating Scale: Data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder

M Berk, S Dodd, O Dean, K Kohlmann, L Berk, G Malhi

(2010), Vol. 22, pp. 237-242, Acta Neuropsychiatrica, C1-1

journal
2009

Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting

M Berk, S Jeavons, O Dean, S Dodd, K Moss, C Gama, G Malhi

(2009), Vol. 14, pp. 357-360, CNS Spectrums, C1-1

journal

Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2009), Vol. 198, pp. 258-262, Behavioural Brain Research, C1-1

journal

Role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice

O Dean, M van den Buuse, A Bush, D Copolov, F Ng, S Dodd, M Berk

(2009), Vol. 16, pp. 2965-2976, Current Medicinal Chemistry, C1-1

journal

Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

M Bernardo, S Dodd, C Gama, D Copolov, O Dean, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush, M Berk

(2009), Vol. 21, pp. 239-245, Acta Neuropsychiatrica, C1-1

journal
2008

N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder-A Double-Blind Randomized Placebo-Controlled Trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush

(2008), Vol. 64, pp. 468-475, Biological Psychiatry, C1-1

journal

N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia-A Double-Blind, Randomized, Placebo-Controlled Trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological Psychiatry, C1-1

journal

Glutathione: a novel treatment target in psychiatry

M Berk, F Ng, O Dean, S Dodd, A Bush

(2008), Vol. 29, pp. 346-351, Trends in Pharmacological Sciences, C1-1

journal

Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications

F Ng, M Berk, O Dean, A Bush

(2008), Vol. 11, pp. 851-876, International Journal of Neuropsychopharmacology, C1-1

journal

N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility

S Dodd, O Dean, D Copolov, G Malhi, M Berk

(2008), Vol. 8, pp. 1955-1962, Expert Opinion on Biological Therapy, C1-1

journal

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological Psychiatry, Philadelphia, Pa., C1-1

journal
2004

A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use

S Jespersen, M Berk, C Van Wyk, O Dean, S Dodd, C Szabo, C Maud

(2004), Vol. 19, pp. 161-164, International Clinical Psychopharmacology, C1-1

journal

Funded Projects at Deakin

Australian Competitive Grants

The Efficacy of N-acetylcysteine as an Adjunctive Treatment in Bipolar Depression: A Double-blind, Randomised, Placebo-controlled Trial

Prof Michael Berk, A/Prof Olivia Dean, A/Prof Susan Cotton, Dr Seetal Dodd, Prof Gin Malhi, A/Prof Chee Ng

NHMRC Project Grant

  • 2015: $69,545
  • 2014: $169,437
  • 2013: $74,883
  • 2012: $197,858

The Efficacy of N-acetylcysteine as an adjunctive treatment in unipolar depression

Prof Michael Berk, Prof Gin Malhi, Dr Seetal Dodd, A/Prof Olivia Dean

NHMRC Project Grant

  • 2012: $32,725
  • 2011: $48,924

Proof of principle of the inflammatory and oxidative theory of depression: A treatment study

Prof Michael Berk, Dr Andrew Chanen, Ms Susan Harrigan, Mr Christopher Davey, Dr Sarah Hetrick, A/Prof Olivia Dean, Dr Seetal Dodd

NHMRC Project Grant

  • 2018: $20,933
  • 2017: $102,975
  • 2016: $152,181
  • 2015: $110,745
  • 2014: $111,704
  • 2013: $105,227
  • 2012: $26,547

The efficacy of adjunctive Garcinia mangostana Linn. pericarp for bipolar depression: A 24-week double-blind, randomized, placebo-controlled trial.

A/Prof Olivia Dean, Prof Michael Berk, A/Prof Chee Ng, Dr Seetal Dodd, Prof Malcolm Hopwood, Dr Alyna Turner, Prof Felice Jacka

NHMRC Project Grant

  • 2019: $231,082
  • 2018: $342,644
  • 2017: $209,758

Integrated exploration of novel therapies for depression

A/Prof Olivia Dean

NHMRC CDF - Career Development Fellowship

  • 2019: $112,441
  • 2018: $120,850

The N-ICE trial: A randomised controlled trial of the safety and efficacy of N-Acetyl Cysteine (NAC) as a pharmacotherapy for methamphetamine ('ice'¿) dependence

A/Prof Rebecca McKetin, A/Prof Olivia Dean, Prof Dan Lubman, Prof Paul Dietze, Dr Peter Higgs, Dr Peter Kelly, Dr Alyna Turner, Dr Brendan Quinn, Prof Greg Carter

NHMRC Project Grant

  • 2019: $114,574
  • 2018: $153,853
  • 2017: $71,859

CREDIT: The CRE for the Development of Innovative Therapies for Psychiatric Disorders

Prof Michael Berk, Prof John McGrath, Prof Patrick McGorry, Prof John McNeil, Prof Gin Malhi, Prof Felice Jacka, A/Prof Susan Cotton, Prof Ken Walder, A/Prof Olivia Dean, A/Prof Lana Williams

NHMRC - Centres of Research Excellence

  • 2019: $467,816

Other Public Sector Funding

Refrigerated Centrifuge and Vortex

Prof Michael Berk, A/Prof Olivia Dean

  • 2015: $8,187

Industry and Other Funding

Efficacy of N-Acetyl Cysteine in Autism: A double blind, placebo-controlled randomised trial

Prof Michael Berk, Dr Seetal Dodd, A/Prof Olivia Dean, Dr Katherine Gray, Prof Bruce Tonge

  • 2013: $143,821
  • 2012: $119,640

The Efficacy of Minocycline as an Adjunctive Treatment in Unipolar Depression: A Pilot Study

A/Prof Olivia Dean

  • 2014: $10,000
  • 2013: $10,000
  • 2012: $10,000

The efficacy of minocycline as an adjunctive therapy for unipolar depression: A pilot study.

A/Prof Olivia Dean

  • 2014: $35,973
  • 2013: $13,966

The efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for the treatment of Schizophrenia: A double-blind, randomized, placebo controlled trial.

Prof Michael Berk, Dr Seetal Dodd, A/Prof Olivia Dean, Dr Alyna Turner, A/Prof Susan Cotton, Prof John McGrath, Dr Frances Dark

  • 2019: $32,055
  • 2018: $167,831
  • 2017: $363,170
  • 2016: $239,559

Exploring inflammation in depression ¿ Minocycline compared with N-acetyl cysteine.

A/Prof Olivia Dean

  • 2017: $10,000
  • 2016: $20,000

The efficacy of adjunctive Garcinia mangostana linn (mangosteen) pericarp for bipolar depression: A 24-week double-blind, randomised, placebo controlled trial

A/Prof Olivia Dean, Miss Melanie Ashton

  • 2017: $4,250
  • 2016: $30,000

The efficacy of adjunctive Garcinia mangostana linn (mangosteen) pericarp for bipolar depression: A 24-week double-blind, randomised, placebo controlled trial

A/Prof Olivia Dean, Prof Michael Berk, Miss Melanie Ashton

  • 2019: $12,750
  • 2018: $17,000
  • 2017: $13,136
  • 2016: $3,863

Can we reduce tobacco smoking using N-acetylcysteine as a cessation treatment?

Prof Michael Berk, Dr Seetal Dodd, A/Prof Olivia Dean

  • 2018: $25,000
  • 2017: $25,000

Trisno Family Postdoctoral Mental Health Research Fellowship

A/Prof Olivia Dean

  • 2019: $30,000

Supervisions

Principal Supervisor
2019

Melanie Ashton

Thesis entitled: Exploring factors that contribute to treatment response in bipolar depression

Doctor of Philosophy (Medicine), School of Medicine

Associate Supervisor
2018

David Robert Skvarc

Thesis entitled: The Post-Anaesthesia N-Acetyl-Cysteine Cognitive Evaluation (PANACEA) trial

Doctor of Philosophy (Psychology), School of Psychology

2017

Kyoko Hasebe

Thesis entitled: Investigating Neurobiological Mechanisms Linking Depression and Inflammation

Doctor of Philosophy (Medicine), School of Medicine